Literature DB >> 26232300

Experimental progressive emphysema in BALB/cJ mice as a model for chronic alveolar destruction in humans.

Nathachit Limjunyawong1, John M Craig1, H A Daniel Lagassé2, Alan L Scott2, Wayne Mitzner3.   

Abstract

Emphysema, one of the major components of chronic obstructive pulmonary disease (COPD), is characterized by the progressive and irreversible loss of alveolar lung tissue. Even though >80% of COPD cases are associated with cigarette smoking, only a relatively small proportion of smokers develop emphysema, suggesting a potential role for genetic factors in determining individual susceptibility to emphysema. Although strain-dependent effects have been shown in animal models of emphysema, the molecular basis underlying this intrinsic susceptibility is not fully understood. In this present study, we investigated emphysema development using the elastase-induced experimental emphysema model in two commonly used mouse strains, C57BL/6J and BALB/cJ. The results demonstrate that mice with different genetic backgrounds show disparate susceptibility to the development of emphysema. BALB/cJ mice were found to be much more sensitive than C57BL/6J to elastase injury in both a dose-dependent and time-dependent manner, as measured by significantly higher mortality, greater body weight loss, greater decline in lung function, and a greater loss of alveolar tissue. The more susceptible BALB/cJ strain also showed the persistence of inflammatory cells in the lung, especially macrophages and lymphocytes. A comparative gene expression analysis following elastase-induced injury showed BALB/cJ mice had elevated levels of il17A mRNA and a number of classically (M1) and alternatively (M2) activated macrophage genes, whereas the C57BL/6J mice demonstrated augmented levels of interferon-γ. These findings suggest a possible role for these cellular and molecular mediators in modulating the severity of emphysema and highlight the possibility that they might contribute to the heterogeneity observed in clinical emphysema outcomes.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  chronic obstructive pulmonary disease; cytokines; diffusing capacity; lung function; lymphocytes; macrophage

Mesh:

Substances:

Year:  2015        PMID: 26232300      PMCID: PMC4593839          DOI: 10.1152/ajplung.00214.2015

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  88 in total

Review 1.  Epidemiology of advanced lung disease in the United States.

Authors:  E A Bresnitz
Journal:  Clin Chest Med       Date:  1997-09       Impact factor: 2.878

2.  Differential sensitivity of C57BL/6 (M-1) and BALB/c (M-2) macrophages to the stimuli of IFN-gamma/LPS for the production of NO: correlation with iNOS mRNA and protein expression.

Authors:  Jane L Santos; Anderson A Andrade; Adriana A M Dias; Cláudio A Bonjardim; Luiz F L Reis; Santuza M R Teixeira; M Fátima Horta
Journal:  J Interferon Cytokine Res       Date:  2006-09       Impact factor: 2.607

3.  Differences in acute lung response to elastase instillation in two rodent species may determine differences in severity of emphysema development.

Authors:  Andrea Vecchiola; Juan Francisco de la Llera; Rodrigo Ramírez; Pablo Olmos; Cristobal I Herrera; Gisella Borzone
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-04-13       Impact factor: 3.619

4.  The health impact of undiagnosed airflow obstruction in a national sample of United States adults.

Authors:  D B Coultas; D Mapel; R Gagnon; E Lydick
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

5.  The pathology of elastase-induced panacinar emphysema in hamsters.

Authors:  J A Hayes; A Korthy; G L Snider
Journal:  J Pathol       Date:  1975-09       Impact factor: 7.996

6.  Ongoing airway inflammation in patients with COPD who do not currently smoke.

Authors:  S R Rutgers; D S Postma; N H ten Hacken; H F Kauffman; T W van Der Mark; G H Koëter; W Timens
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

7.  Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis.

Authors:  Stephanie Schulte; Galina K Sukhova; Peter Libby
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

Review 8.  Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema.

Authors:  R T Abboud; S Vimalanathan
Journal:  Int J Tuberc Lung Dis       Date:  2008-04       Impact factor: 2.373

9.  IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice.

Authors:  Etsuko Kurimoto; Nobuaki Miyahara; Arihiko Kanehiro; Koichi Waseda; Akihiko Taniguchi; Genyo Ikeda; Hikari Koga; Hisakazu Nishimori; Yasushi Tanimoto; Mikio Kataoka; Yoichiro Iwakura; Erwin W Gelfand; Mitsune Tanimoto
Journal:  Respir Res       Date:  2013-01-20

Review 10.  The M1 and M2 paradigm of macrophage activation: time for reassessment.

Authors:  Fernando O Martinez; Siamon Gordon
Journal:  F1000Prime Rep       Date:  2014-03-03
View more
  19 in total

1.  Basophils trigger emphysema development in a murine model of COPD through IL-4-mediated generation of MMP-12-producing macrophages.

Authors:  Sho Shibata; Kensuke Miyake; Tomoya Tateishi; Soichiro Yoshikawa; Yoshinori Yamanishi; Yasunari Miyazaki; Naohiko Inase; Hajime Karasuyama
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

2.  Automated full-range pressure-volume curves in mice and rats.

Authors:  Annette Robichaud; Liah Fereydoonzad; Nathachit Limjunyawong; Richard Rabold; Benoit Allard; Andrea Benedetti; James G Martin; Wayne Mitzner
Journal:  J Appl Physiol (1985)       Date:  2017-07-27

3.  Reply to: Quantitative Histology Seriously Flawed by Lack of Lung Volume Measurement.

Authors:  Josiah E Radder; Steven D Shapiro
Journal:  Am J Respir Cell Mol Biol       Date:  2018-02       Impact factor: 6.914

4.  Second harmonic generation imaging of collagen scaffolds within the alveolar ducts of healthy and emphysematous mouse lungs.

Authors:  Wayne Mitzner; Tillie L Hackett; Leila B Mostaco-Guidolin; Jeffrey Loube; Aaron Barlow; Emmanuel T Osei; Dragoș M Vasilescu; Aileen Hsieh; May Fouadi; Christine Young; Alan L Scott
Journal:  Histochem Cell Biol       Date:  2021-01-30       Impact factor: 4.304

Review 5.  Immune-mediated inflammation in the pathogenesis of emphysema: insights from mouse models.

Authors:  John M Craig; Alan L Scott; Wayne Mitzner
Journal:  Cell Tissue Res       Date:  2017-02-06       Impact factor: 5.249

6.  Gallic acid protects against the COPD-linked lung inflammation and emphysema in mice.

Authors:  Esha Singla; Vivek Dharwal; Amarjit S Naura
Journal:  Inflamm Res       Date:  2020-03-06       Impact factor: 4.575

Review 7.  Oscillometry of the respiratory system: a translational opportunity not to be missed.

Authors:  Lennart K A Lundblad; Annette Robichaud
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-04-06       Impact factor: 5.464

8.  Airway compliance measurements in mouse models of respiratory diseases.

Authors:  Annette Robichaud; Liah Fereydoonzad; Samuel L Collins; Jeffrey Martin Loube; Yumiko Ishii; Maureen R Horton; James G Martin; Wayne Mitzner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-05-19       Impact factor: 6.011

9.  Dual interleukin-17A/F deficiency protects against acute and chronic response to cigarette smoke exposure in mice.

Authors:  Hiroo Wada; Masuo Nakamura; Shin-Ichi Inoue; Akihiko Kudo; Tomoko Hanawa; Yoichiro Iwakura; Fumie Kobayashi; Hiroshi Kamma; Shigeru Kamiya; Kazuhiro Ito; Peter J Barnes; Hajime Takizawa
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

10.  Therapeutic treatment of dietary docosahexaenoic acid for particle-induced pulmonary inflammation in Balb/c mice.

Authors:  Paige Fletcher; Raymond F Hamilton; Joseph F Rhoderick; Britten Postma; Mary Buford; James J Pestka; Andrij Holian
Journal:  Inflamm Res       Date:  2021-02-10       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.